register

News & Trends - MedTech & Diagnostics

Launch of first infusion set to double wear time in type 1 diabetes

Health Industry Hub | June 17, 2024 |

MedTech & Diagnostics News: Traditionally, insulin infusion sets used by adults with type 1 diabetes are replaced every 2 to 3 days to prevent complications and diabetic ketoacidosis due to set failure. Medtronic is set to launch the first and only extended insulin infusion set in Australia, which can be worn for up to 7 days.

The new extended infusion set, developed in collaboration with ConvaTec, will be available through the National Diabetes Services Scheme (NDSS) starting July 1, 2024.

The introduction of this extended infusion set comes at a time when, despite increasing diabetes incidence rates, advancements in health technology have significantly improved glycaemic outcomes and health-related quality of life for patients.

Medtronic’s single-arm, non-randomised trial assessed the safety and performance of the new medical device in 259 individuals aged 18 to 80. Participants first used traditional 2- or 3-day infusion sets with the MiniMed 670G system for two weeks, followed by twelve consecutive wears of the Medtronic Extended infusion set.

The trial results showed that the extended infusion set had a survival rate of 77.8% for the 7-day wear period. Importantly, glycaemic control remained stable, and participants reported significantly greater satisfaction with the new set compared to the standard one (P < 0.001).

One of the major benefits highlighted by Medtronic is the potential for substantial cost savings. These savings stem from reduced insulin wastage during set changes, a 12-fold decrease in adverse effects related to device failure, and a significant reduction in plastic waste.

Standard infusion sets and reservoirs, which last 2 to 3 days, generate considerable medical waste; each patient uses between 120 to 180 sets and cartridges annually. In contrast, users of the extended infusion set will change their sets approximately 75 fewer times per year, reducing medical waste by about 40% to 60%.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Clinical and Laboratory Haematologist and Lead of the Molecular Haematology Service

Clinicians call for closer monitoring of patients post CAR T therapy

Health Industry Hub | February 17, 2025 |

Australian clinicians are raising questions about whether cancer patients need closer monitoring after receiving CAR T-cell therapy. A Peter MacCallum […]

More


News & Trends - MedTech & Diagnostics

Next-gen surgical mesh to fill critical gap after ban

Next-gen surgical mesh to fill critical gap after regulatory ban

Health Industry Hub | February 17, 2025 |

Next-generation urogynaecological surgical mesh implants are on the horizon for women suffering from pelvic organ prolapse (POP). This development aims […]

More


News & Trends - Pharmaceuticals

Contraceptive lawsuit against Bayer fails

Contraceptive lawsuit against Bayer fails

Health Industry Hub | February 17, 2025 |

The Victorian Supreme Court has dismissed a class action against Bayer for an allegedly defective contraceptive device. Justice Andrew Keogh […]

More


News & Trends - Pharmaceuticals

NSW Government ignored warnings since 2018: Mental health system unravels as psychiatrists quit en masse

NSW Government ignored warnings since 2018: Mental health system unravels as psychiatrists quit en masse

Health Industry Hub | February 17, 2025 |

The New South Wales Labor government’s plan to “redesign” the state’s mental health system, while excluding psychiatrists, has sparked intense […]

More


This content is copyright protected. Please subscribe to gain access.